These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 8585542)
21. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846 [TBL] [Abstract][Full Text] [Related]
22. Docetaxel weekly with metastatic breast cancer. Twelves C Onkologie; 2007 Sep; 30(8-9):407-8. PubMed ID: 17848810 [No Abstract] [Full Text] [Related]
23. Finding the right dose for cancer therapeutics--can we do better? Rubin EH; Anderson KM Clin Cancer Res; 2010 Feb; 16(4):1085-7. PubMed ID: 20145182 [TBL] [Abstract][Full Text] [Related]
24. Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo? Crown J Lancet; 2003 Aug; 362(9385):677-8. PubMed ID: 12957087 [No Abstract] [Full Text] [Related]
25. Mechanisms to improve chemotherapy effectiveness. Young RC Cancer; 1990 Feb; 65(3 Suppl):815-22. PubMed ID: 2406004 [TBL] [Abstract][Full Text] [Related]
27. 'Flat-fixed dosing' of chemotherapy: a concept whose time has come? Markman M Curr Oncol Rep; 2005 Jan; 7(1):1-2. PubMed ID: 15610676 [No Abstract] [Full Text] [Related]
28. NCCN: High-dose chemotherapy. Applications of high-dose chemotherapy with bone marrow/stem cell support in solid tumors. Vaughan WP Cancer Control; 2001; 8(6 Suppl 2):50-2. PubMed ID: 11760558 [No Abstract] [Full Text] [Related]
29. Is high-dose intensity intraarterial cisplatin chemoradiotherapy for head and neck carcinoma feasible? Robbins KT Cancer; 2005 Feb; 103(3):447-50. PubMed ID: 15633205 [No Abstract] [Full Text] [Related]
30. Chemotherapy dose intensity facilitated by use of lenograstim--implications for quality of life and survival. Gisselbrecht C Eur J Cancer; 1994; 30A Suppl 3():S30-3. PubMed ID: 7535070 [TBL] [Abstract][Full Text] [Related]
31. Optimizing the management of chemotherapy-induced neutropenia. Dale DC Clin Adv Hematol Oncol; 2003 Nov; 1(11):679-84. PubMed ID: 16258470 [TBL] [Abstract][Full Text] [Related]
33. Minimalism in oncology. The Lancet Oncology Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372 [No Abstract] [Full Text] [Related]
34. The rationale of dose-response curves in selecting cancer drug dosing. Martin JH; Dimmitt S Br J Clin Pharmacol; 2019 Oct; 85(10):2198-2204. PubMed ID: 31077412 [TBL] [Abstract][Full Text] [Related]
35. Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. Lasala R; Santoleri F; Romagnoli A; Musicco F; Costantini A Eur J Clin Pharmacol; 2019 May; 75(5):697-706. PubMed ID: 30617511 [TBL] [Abstract][Full Text] [Related]
36. Topotecan: what dose, what schedule, what route? O'Reilly S Clin Cancer Res; 1999 Jan; 5(1):3-5. PubMed ID: 9918195 [No Abstract] [Full Text] [Related]
37. Average relative dose intensity and the impact on design of clinical trials. Hryniuk WM Semin Oncol; 1987 Mar; 14(1):65-74. PubMed ID: 3823917 [No Abstract] [Full Text] [Related]
38. Several apparent errors surfaced on reading the article in the June 2002 issue of Alternative Medicine Review by Kodama et al. entitled "Can maitake MD-fraction aid cancer patients"? Black W Altern Med Rev; 2002 Dec; 7(6):451; author reply 452-4. PubMed ID: 12495370 [No Abstract] [Full Text] [Related]
39. Clinical cancer chronotherapy trials: a review. Bjarnason GA J Infus Chemother; 1995; 5(1):31-7. PubMed ID: 7634175 [TBL] [Abstract][Full Text] [Related]
40. Cytotoxic drugs: the search for dose response. Dodwell DJ Lancet; 1993 Mar; 341(8845):614-6. PubMed ID: 8094841 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]